Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth

  1. William R. Sellers1,
  2. Bennett G. Novitch2,
  3. Satoshi Miyake1,
  4. Agnieszka Heith1,
  5. Gregory A. Otterson3,
  6. Frederic J. Kaye3,
  7. Andrew B. Lassar2, and
  8. William G. Kaelin, Jr.1,4
  1. 1The Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115 USA; 2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115 USA; 3National Cancer Institute–Navy Medical Oncology Branch, Division of Clinical Sciences, Bethesda, Maryland 20889 USA

Abstract

The retinoblastoma tumor suppressor protein (pRB) can inhibit cell cycle progression and promote differentiation. pRB interacts with a variety of transcription factors, including members of the E2F and C-EBP protein families and MyoD, and can either repress or activate transcription depending on the promoter under study. These biological and biochemical activities of pRB have been mapped previously to a core domain, referred to as the pRB pocket. Using a panel of synthetic pRB pocket mutants, we found that the acute induction of a G1/S block by pRB is linked to its ability to both bind to E2F and to repress transcription. In contrast, these functions were not required for pRB to promote differentiation, which correlated with its ability to activate transcription in concert with fate-determining proteins such as MyoD. All tumor-derived pRB mutants tested to date failed to bind to E2F and did not repress transcription. Despite an inability to bind to E2F, pRB mutants associated with a low risk of retinoblastoma, unlike high-risk mutants, retained the ability to activate transcription and promote differentiation. Thus, the pRB pocket participates in dual tumor suppressor functions, one linked to cell cycle progression and the other to differentiation control, and these functions can be genetically and mechanistically dissociated.

Keywords

Footnotes

  • 4 Corresponding author.

  • E-MAIL William_Kaelin{at}dfci.harvard.edu; FAX (617) 632-4381.

    • Received September 29, 1997.
    • Accepted November 6, 1997.
| Table of Contents

Life Science Alliance